Department of Pathology & Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, U,S,A, BOX 951732, 1P-244 CHS Los Angeles, CA 90095-1732 USA.
Diagn Pathol. 2010 Aug 20;5:54. doi: 10.1186/1746-1596-5-54.
Presence of lobular intraepithelial neoplasia (LIN) is not routinely reported as part of margin assessment in breast conservation therapy (BCT) as in ductal carcinoma in situ (DCIS). With new emerging evidence of LIN as possible precursor lesion, the hypothesis is that LIN at the margin may increase the risk of local recurrence with BCT. The aim is to determine whether there is an increase incidence of recurrence when LIN is found at surgical margins on BCT.
We retrospectively reviewed a total of 1,334 BCT at a single institution in a 10 year period. Inclusion criteria are positive margin with LIN from primary BCT containing invasive and/or in situ carcinoma with comparison to the negative control group who had similar diseases with negative margin for LIN.
We identified 38 cases (2.8%) with LIN either lobular carcinoma in situ/atypical lobular hyperplasia (LCIS/ALH) at a margin on initial BCT with 36% recurrence rate. Of the 38 cases: 5 (13%) were lost to follow-up, 12 (32%) had no further procedures performed and 21 (55%) had re-excision. Out of 21 patients who had re-excisions, 12 (57%) had residual invasive carcinoma or DCIS, three (14%) had pleomorphic LCIS and 4 (19%) showed residual classic type LCIS. 71% had significant residual disease (local recurrence) and 29% had no residual disease. A negative control group consisted of 38 cases. We found two patients with bone or brain metastasis and one local recurrence. Clinical follow up periods range from 1 to 109 months.
LIN found at a margin on BCT showed a significant recurrent ipsilateral disease. Our study supports the view that LIN seen at the margin may play a role in recurrence.
在保乳治疗 (BCT) 中,不像导管原位癌 (DCIS) 那样,通常不会报告小叶内上皮内瘤变 (LIN) 的存在作为边缘评估的一部分。随着 LIN 作为可能的前病变的新出现证据,假设在 BCT 中,边缘处的 LIN 可能会增加局部复发的风险。目的是确定在 BCT 的手术边缘处发现 LIN 时是否会增加复发的发生率。
我们回顾性分析了一家机构在 10 年期间的总共 1334 例 BCT。纳入标准是原发性 BCT 中存在 LIN 阳性的边缘,其中包括浸润性和/或原位癌,并与 LIN 阴性对照的相似疾病的阴性边缘进行比较。
我们在初始 BCT 的边缘处发现了 38 例(2.8%)具有 LIN 的病例,其中包括 LCIS/ALH 小叶癌原位/不典型小叶增生,复发率为 36%。在 38 例病例中:5 例(13%)失访,12 例(32%)未进一步进行手术,21 例(55%)进行了再次切除。在 21 例接受再次切除的患者中,12 例(57%)有残留浸润性癌或 DCIS,3 例(14%)有多形性 LCIS,4 例(19%)显示残留经典型 LCIS。71%有明显的残留疾病(局部复发),29%没有残留疾病。阴性对照组包括 38 例病例。我们发现 2 例患者有骨或脑转移,1 例有局部复发。临床随访时间从 1 到 109 个月不等。
在 BCT 的边缘处发现的 LIN 显示出明显的同侧疾病复发。我们的研究支持这样一种观点,即在边缘处发现的 LIN 可能在复发中起作用。